Engagement of the CrkL adaptor in interferon α signalling in BCR-ABL-expressing cells

British Journal of Haematology

Volumn 112, Issue 2, 2001, Pages 327-336

  Grumbach, Isabella M ^a   Mayer, Ingrid A ^a   Uddin, Shahab ^a   Lekmine, Fatima ^a   Majchrzak, Beata ^b,c   Yamauchi, Hayato ^d   Fujita, Shigeru ^d   Druker, Brian J ^e   Fish, Eleanor N ^b,c   Platanias, Leonidas C ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic myelogenous leukaemia; Interferon; Tyrosine kinases

Indexed keywords

ADAPTOR PROTEIN; BCR ABL PROTEIN; CRK LIKE PROTEIN; INTERFERON RECEPTOR; PHOSPHOPROTEIN; RAP PROTEIN; RECOMBINANT ALPHA INTERFERON; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CELL LINE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; DNA-BINDING PROTEINS; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOBLOTTING; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MILK PROTEINS; NUCLEAR PROTEINS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0035120788     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02556.x     Document Type: Article

References (48)

1. The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein
2. IFNγ activates the C3G-Rap1 signaling pathway
3. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts
4. Maintenance of human T cell anergy: Blocking of IL-2 gene transcription by activated Rap1
5. RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts
6. The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway
7. Blast crisis in a routine model of chronic myelogenous leukemia
8. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
9. BCR/ABL-induced leukemogenesis causes phosphorylation of Hef1 and its association with Crkl
10. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines
11. Activation of a CrkL-Stat5 signaling complex by type I interferons
12. Application of genomic DNA affinity chromatography identifies multiple interferon-alpha-regulated Stat2 complexes
13. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene
14. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
15. Direct binding of CrkL to BCR-ABL is not required for BCR-ABL transformation
16. Structural organization of the bcr gene and its role in the Ph' translocation
17. A ras-related gene with transformation suppressor activity
18. Genetic analysis of the Kirsten-ras-revertant 1 gene: Potentiation of its tumor suppressor activity by specific point mutations
19. Interplay of the proto-oncogene proteins CrkL and CrkII in insulin-like growth factor-receptor-mediated signal transduction
20. Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210 BCR/ABL
21. Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells
22. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH) 3 and SH2 domains of BCR/ABL and is required for leukemogenesis
23. CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3
24. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia
25. BCR/ABL mRNA and the P210 (BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients
26. Interferon alpha induces rapid tyrosine phosphorylation of the vav proto-oncogene product in hematopoietic cells
27. Signaling pathways activated by interferons
28. The type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2
29. CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors
30. Costimulation through CD28 suppresses T cell receptor-dependent activation of the Ras-like small GTPase Rap1 in human T lymphocytes
31. CrkL functions as a nuclear adaptor and transcriptional activator in BCR-ABL-expressing cells
32. The product of the cbl oncogene forms stable complexes in vivo with endogenous Crk in a tyrosine phosphorylation-dependent manner
33. The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190 BCR/ABL and p210 BCR/ABL to the phosphatidylinositol-3′ kinase pathway
34. The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors
35. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the BCR-ABL oncogene
36. Transcriptional induction of the PML growth suppressor gene by interferons is mediated throughan ISRE and a GAS element
37. How cells respond to interferons
38. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia
39. Interferon-alpha engages the insulin receptor substrateto associate with the phosphatidylinositol 3′-kinase
40. Insulin-dependent tyrosine phosphorylation of the vav protooncogene product in cells of hematopoietic origin
41. Activation of the phosphatidylinositol 3-kinase serine kinase by interferon α
42. The IRS-pathway operates distinctively from the Stat-pathway in hematopoietic cells and transduces common and distinct signals during engagement of the insulin or interferon-alpha receptors
43. The vav proto-oncogene product (p95vav) interacts with the Tyk-2 protein tyrosine kinase
44. Activation of the p38 mitogen-activated protein kinase by type I interferons
45. The Rac1/p38 Map kinase pathway is required for IFNα-dependent transcriptional activation but not serine phosphorylation of Stat-proteins
46. The BCR/ABL oncogene alters interaction of the adaptor proteins CRKL and CRK with cellular proteins
47. Interferon-alpha therapy for chronic myelogenous leukemia
48. Suppression of cell proliferation and the expression of a BCR-ABL fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line. KT-1 by interferon-alpha